Potential to become a new modality in the treatment of ulcerative colitis offering prolonged remission without immune ...
Microbiotica has announced positive results in its Phase 1b First-in-Human trial, COMPOSER-1, of MB310 in ulcerative colitis (UC) patients.
Dear Dr. Roach: I am a 64-year-old female who is in moderate health. After a monthslong bout of diarrhea, blood work, and a colonoscopy, I’ve been diagnosed with microscopic colitis. After a round of ...
Dear Dr. Roach: I am a 64-year-old female who is in moderate health. After a monthslong bout of diarrhea, blood work, and a colonoscopy, I’ve been diagnosed with microscopic colitis. After a round of ...
Analysis of 11 trials shows that some advanced treatments relieve symptoms faster and produce better short-term responses in ...
DEAR DR. ROACH: I am a 64-year-old female who is in moderate health. After a monthslong bout of diarrhea, blood work, and a colonoscopy, I’ve been diagnosed with microscopic colitis. After a round of ...
News-Medical.Net on MSN
Blood markers can indicate people at risk of developing ulcerative colitis
Researchers at örebro University have identified blood markers that can indicate who is at risk of developing ulcerative ...
Microscopic colitis (MC) is a chronic inflammatory bowel disease that severely reduces quality of life. MC is responsible for over 30% of all chronic diarrhea cases in people over 65 years of age, and ...
Phase 3 results suggest intravenous vedolizumab is effective and safe for clinical remission in pediatric patients with moderate to severe UC.
Some results have been hidden because they may be inaccessible to you
Show inaccessible results